Increased serum interleukin-6 and lactate dehydrogenase levels among nonsurvival severe COVID-19 patients when compared to survival ones

Haroun, Riham Abdel-Hamid; Osman, Waleed H.; Amin, Rasha E.; Eessa, Asmaa M.; Saad, S.S.

doi:10.1016/j.intimp.2023.110626

Cited by 5 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is reported that severe COVID-19 patients have lymphopenia with a significant decrease in the B cells, NK cells, CD4+ T cells and CD8+ T cells, along with a reduced number of eosinophils, monocytes and basophils. In addition to this, the cytokines storm and chemokines such as TNF-α, MCP1, MIP1b, PDGFB, IL1-b, IL1Ra, IL6, IL7, IL8, IL9, IL10, Fibroblast growth factor 2, GCSF, GMCSF, IFNc, IP10, and VEGFA were found to be significantly increased in the COVID-19 patients [71][72]; which subsequently resulting in acute respiratory distress syndrome (ARDS), multiple organ failure and eventually death in the extreme cases of SARS-CoV-2 infection [69].…”

Section: Immunopathological Responses To Sars-cov-2 Infectionmentioning

confidence: 89%

“…COVID-19 patients, especially critical patients, are at higher risk of developing acute kidney injury (AKI), which was reported to be a risk factor for mortality [87]. It was reported that AKI develops in about 0.5-7% of COVID-19 patients and this proportion raised to 2.9-23% in COVID-19 critically ill patients [7,71,88]. In China; there is a centric prospective cohort study including 701 COVID-19 patients who reported that there were 43.9% of patients with proteinuria 26.7% with hematuria on admission and 5.1% developed AKI during hospitalization [85].…”

Section: Renal Complicationsmentioning

confidence: 99%

See 1 more Smart Citation

Historical Perspectives of SARS-CoV-2 Viral Subversion of Host Cell: Biochemical and Pathological Aspects

Hamid Haroun,

H. Osman

2023

Applied Microbiology: Theory ＆ Technology

View full text Add to dashboard Cite

The pandemic of coronavirus disease-19 (COVID-19) was a worldwide health crisis affecting many more people than 221 countries causing life-threatening complications and indirectly affecting even more individuals through disruption of daily living. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a member of beta-coronavirus having RNA as a genetic material sharing 79% similarity with the bat SARS-CoV genome. The SARS-CoV-2 enters the host cells by binding specifically to the angiotensin-converting enzyme-2 (ACE-2) which is expressed on the surface of epithelial cells in the respiratory tract, intestine, kidneys, and others causing severe acute respiratory failure and other complications. In addition to respiratory symptoms, uncontrolled SARS-CoV-2 infection can induce a cytokine storm, whereby pro-inflammatory cytokines and chemokines such as IL-6, TNF-α, and IL-1β are increased, which in turn leads to multiorgan damage. Herein, we described the history and classification of coronaviruses, geographical distribution of COVID-19, SARS-CoV-2 structure and genomic organization, life cycle, immunopathological responses, symptoms, and finally pulmonary and extra-pulmonary complications of SARS-CoV-2 infection.

show abstract

Section: Immunopathological Responses To Sars-cov-2 Infectionmentioning

confidence: 89%

Section: Renal Complicationsmentioning

confidence: 99%

Historical Perspectives of SARS-CoV-2 Viral Subversion of Host Cell: Biochemical and Pathological Aspects

Hamid Haroun,

H. Osman

2023

Applied Microbiology: Theory ＆ Technology

View full text Add to dashboard Cite

show abstract

“…We pointed out that, in addition to elevated levels of serum PCT, other inflammatory markers, including serum LDH and D-dimer levels, were significantly higher in non-survivors of severe to critical COVID-19 patients as compared to survivors. In a prospective observational study of 180 severe COVID-19 patients, levels of neutrophil percentage, C-reactive protein (CRP), IL-6, PCT, and LDH were significantly higher in non-survivors [ 22 ]. The authors also observed that IL-6 and LDH were the most sensitive and specific markers for predicting mortality among severe COVID-19 patients.…”

Section: Discussionmentioning

confidence: 99%

Utility of Serum Procalcitonin and Its Clearance in Predicting Outcomes in COVID-19 Patients

Mehfooz,

Shah,

Siraj

et al. 2024

Cureus

View full text Add to dashboard Cite

Identification of coronavirus disease 2019 (COVID-19) patients at risk of worse clinical outcomes is crucial to improving patient care. Various biochemical markers have been used to predict outcomes in such patients. We aimed to evaluate the role of serum PCT (procalcitonin) and the utility of PCT clearance (PCTc) in predicting the outcome of patients with COVID-19 illness. MethodsWe prospectively included 39 patients with severe or critical COVID-19 illness with an age equal to more than 18 years. In addition to routine baseline investigations, serum PCT was measured at admission (PCT1) and day 5 of hospitalization (PCT2). PCTc was calculated using the formula . ResultsWe observed that serum PCT at admission was significantly higher in non-survivors (median: 1.9 ng/ml IQR: 0.51-4.23) compared to survivors (median 0.35 (IQR: 0.1-1.2), p 0.002). On serial serum-PCT estimation, non-survivors had persistently elevated serum-PCT (median PCT1:1.9 ng/ml (IQR: 0.51-4.23) to median PCT2: 1.9ng/ml (IQR: 0.83-2.72), p 0.51) than survivors (median PCT1:0.35ng/ml (IQR: 0.1-1.19) to median PCT2: 0.15ng/ml (IQR: 0.05-0.29), p 0.01). However, no difference in serum PCTc was observed between the two groups (median: 35.3% (IQR: 12.5-84.9) in survivors vs. 71.7% (33.3-91.7) in non-survivors, p = 0.165). ConclusionSerum PCT is a potential biochemical marker that could predict outcomes in COVID-19 patients. Measurement of serial serum PCT and estimation of PCT clearance may serve as better predictors than a single value; however, well-designed studies are required to identify the definite role of serum PCT in COVID-19 patients of varying severity.

show abstract

“…A later meta-analysis confirmed the value of IL-6 for predicting severe progression but not mortality ( Liu et al, 2022 ). However, a recent single center study was able to show the predictive capacity of IL-6 for survival among a cohort of severe COVID-19 cases ( Haroun et al, 2023 ). In the present study, we could show that serum IL-6 levels can also predict COVID-19 progression in a cohort of patients with a high proportion of hospitalized moderate cases.…”

Section: Discussionmentioning

confidence: 99%

Serum interleukin-6, procalcitonin, and C-reactive protein at hospital admission can identify patients at low risk for severe COVID-19 progression

Zobel,

Wenzel,

Krüger

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

BackgroundCOVID-19 can show a variable course, from asymptomatic infections to acute respiratory failure and death. For efficient allocation of resources, patients should be stratified according to their risk for a severe course as early as possible.Methods135 hospitalized patients with COVID-19 pneumonia at four German hospitals were prospectively included in this observational study. A standardized clinical laboratory profile was taken at hospital admission and a panel of serum markers with possible roles in the COVID-associated cytokine storm were also determined. 112 patients could be evaluated. The primary endpoint of ventilator requirement or death within 30 days of symptom onset was met by 13 patients.ResultsSerum elevations of interleukin-6 (IL-6), procalcitonin (PCT), and C-reactive protein (CRP) at hospital admission were each highly significantly (p < 0.001) associated with ventilator requirement/death within 30 days of symptom onset. With a sensitivity of 92% and a specificity of 65–67%, IL-6 ≥ 52.8 pg/ml, PCT ≥ 0.11 ng/ml, and CRP ≥ 71.1 mg/L were predictive of a severe course of COVID-19. Positive likelihood ratios were between 2.6–2.8 and negative likelihood ratios were between 0.11–0.13 for these three markers.ConclusionNegative likelihood ratios indicate that IL-6, PCT, and CRP at hospital admission can be used for identifying patients at low risk for severe COVID-19 progression.

show abstract

Increased serum interleukin-6 and lactate dehydrogenase levels among nonsurvival severe COVID-19 patients when compared to survival ones

Cited by 5 publications

References 35 publications

Historical Perspectives of SARS-CoV-2 Viral Subversion of Host Cell: Biochemical and Pathological Aspects

Historical Perspectives of SARS-CoV-2 Viral Subversion of Host Cell: Biochemical and Pathological Aspects

Utility of Serum Procalcitonin and Its Clearance in Predicting Outcomes in COVID-19 Patients

Serum interleukin-6, procalcitonin, and C-reactive protein at hospital admission can identify patients at low risk for severe COVID-19 progression

Contact Info

Product

Resources

About